Search Result

Results for "

Lipoxin A-4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Endogenous Metabolite (2) Formyl Peptide Receptor (FPR) (1) Interleukin Related (2) STAT (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Inflammation/Immunology (7) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113509

Lipoxin A4 1 Publications Verification LXA4	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties . Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways . Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM .

HY-100450

BML-111	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Inflammation/Immunology Cancer
BML-111, a lipoxin A₄ analog, is a lipoxin A₄ receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties .

HY-124071

ACT-389949	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
ACT-389949 is a first-in-class, potent and selective and agonist of *formyl peptide receptor type 2 (FPR2)/Lipoxin* A4 receptor (ALX), with an EC₅₀** of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders .

HY-126722

Lipoxin A4 methyl ester	Others	Inflammation/Immunology
Lipoxin A4 methyl ester is a stable synthetic analog of lipoxin with anti-inflammatory properties that can be extracted from arachidonic acid .

HY-113509S

Lipoxin A4-d5 LXA4-d₅	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-113509B

*15(R)-Lipoxin* A4** 15-epi-LXA4	STAT	Neurological Disease Inflammation/Immunology
15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve the phagocytic function of microglia and exhibits anti-inflammatory activity. In Alzheimer's disease (AD) mouse models, 15(R)-Lipoxin A4 improves AD-like pathology. 15(R)-Lipoxin A4 holds potential for use in inflammation and neurodegenerative disease research .

HY-113509A

*6-epi-Lipoxin* A4** 6-epi-LXA4	Others	Others
6-epi-Lipoxin A4 is an active compound.

HY-112621

Leukotriene A4 methyl ester LTA4 methyl ester	Others	Inflammation/Immunology
Leukotriene A4 (LTA4) is synthesized in mast cells, eosinophils, and neutrophils from arachidonic acid by 5-lipoxygenase (5-LO), which exhibits both lipoxygenase and LTA4 synthase activities. LTA4 is rapidly metabolized by LTA4 hydrolase or LTC4 synthase to LTB4 or LTC4, respectively.2 LTA4, from leukocytes, is known to undergo transcellular metabolism in platelets, erythrocytes, and endothelial cells.3 Further metabolism of LTA4 by 15-LO leads to lipoxin biosynthesis.2 LTA4 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113509

Lipoxin A4 1 Publications Verification LXA4	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Interleukin Related Endogenous Metabolite
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties . Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways . Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM .

HY-113509B

*15(R)-Lipoxin* A4** 15-epi-LXA4	Structural Classification Natural Products Source classification	STAT
15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve the phagocytic function of microglia and exhibits anti-inflammatory activity. In Alzheimer's disease (AD) mouse models, 15(R)-Lipoxin A4 improves AD-like pathology. 15(R)-Lipoxin A4 holds potential for use in inflammation and neurodegenerative disease research .

Cat. No.	Product Name	Chemical Structure

HY-113509S

Lipoxin A4-d5
Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

Lipoxin A4-d5

Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks